Equities

Fuso Pharmaceutical Industries Ltd

4538:TYO

Fuso Pharmaceutical Industries Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,182.00
  • Today's Change-176.00 / -7.46%
  • Shares traded42.60k
  • 1 Year change+8.72%
  • Beta0.9314
Data delayed at least 20 minutes, as of Mar 28 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fuso Pharmaceutical Industries, Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceuticals and medical equipment for medical purposes. The Company operates in two business segments. The Pharmaceuticals segment is involved in manufacture and sale of pharmaceutical products, including injectable drugs, which mainly focus on infusion solution, dialysis fluid for artificial kidney, as well as the manufacture and sale of medical equipment and instruments. The Real Estate segment is engaged in the leasing of real estate properties.

  • Revenue in JPY (TTM)54.63bn
  • Net income in JPY1.34bn
  • Incorporated1937
  • Employees1.31k
  • Location
    Fuso Pharmaceutical Industries Ltd1-7-10, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
  • Phone+81 662316887
  • Fax+81 669692341
  • Websitehttps://www.fuso-pharm.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Oncolys Biopharma Inc63.04m-1.94bn12.68bn33.00--8.32--201.10-108.23-108.233.5475.100.02692.190.3001---82.64-45.75-97.13-51.8648.5560.46-3,075.14-233.665.15--0.1761---93.54-17.86-68.72--28.18--
Nano Mrna Co Ltd164.39m-1.05bn12.74bn17.00--3.66--77.51-14.94-14.942.3449.400.029518.962.609,669,765.00-18.85-25.13-23.29-26.0480.6784.69-638.22-538.318.95--0.2418---23.42-4.8430.33------
Medinet Co Ltd724.63m-1.41bn12.78bn98.00--2.19--17.64-6.31-6.313.2322.880.122411.933.617,394,143.00-23.74-21.05-24.75-22.4717.7228.75-193.90-135.4019.58--0.00--4.40-7.90-14.66---17.67--
RaQualia Pharma Inc1.90bn-323.66m13.10bn65.00--2.14--6.89-14.99-14.9987.98283.050.28963.133.15---4.932.13-5.292.2687.1188.49-17.025.3212.35--0.05670.00-34.8520.62-144.74--0.0967--
AnGes Inc152.99m-7.04bn13.28bn138.00--0.4942--86.81-37.36-37.360.8083133.560.00450.10378.40---20.73-28.23-24.14-32.7812.7139.42-4,599.32-6,665.172.00--0.0135--128.13-24.1752.18--12.11--
ReproCell Inc2.51bn-217.49m13.76bn92.00--1.72--5.49-2.56-2.5629.4890.900.30084.867.4427,247,390.00-2.61-9.37-2.80-10.1143.5538.78-8.68-38.1211.94--0.00--32.1626.1046.91--28.24--
Ohki Healthcare Holdings Co Ltd327.51bn2.35bn14.26bn576.005.950.52925.370.0435170.32170.3223,747.191,914.312.3711.644.27568,593,700.001.651.957.989.115.207.120.69620.75390.8536--0.1913.289.454.91124.49-1.16-1.279.46
Microwave Chemical Co Ltd1.89bn98.88m15.80bn59.00227.389.2689.778.364.454.45116.78109.320.65269.376.5332,055,120.003.41--4.65--54.51--5.23--2.6511.240.2309--41.24--168.39------
TAIKO PHARMACEUTICAL CO LTD6.12bn-3.61bn19.50bn210.00--2.85--3.19-73.48-73.48129.22134.920.4332.133.24---25.54---32.19--42.11---58.99--2.54--0.3256--21.43--26.23------
Astena Holdings Co Ltd51.98bn1.16bn19.92bn1.40k16.520.67555.910.383229.4229.421,317.36719.530.79483.522.9137,025,940.001.762.493.174.4431.3925.332.222.320.9038--0.372744.924.73-2.85100.61-3.8538.5411.38
Fuso Pharmaceutical Industries Ltd54.63bn1.34bn22.29bn1.31k15.220.55316.320.408154.89154.896,295.264,263.410.7253.312.2041,572,300.001.781.792.952.8725.2927.782.452.591.0965.130.283545.952.792.148.2310.60-1.72-2.64
Medical Data Vision Co Ltd6.42bn979.13m24.30bn257.0023.695.4523.003.7925.6325.63168.05111.301.15140.016.11--17.1716.1624.0120.8878.3881.9014.8715.522.5824.66--19.985.1512.4012.4869.75-23.95--
Cuorips Inc39.89m-598.68m26.74bn46.00--4.42--670.25-76.49-76.495.13766.300.00813.9339.73867,130.40-12.10---12.39--45.79---1,500.91--35.89--0.00--175.12---20.45------
Pharma Foods International Co., Ltd.65.08bn4.76bn27.39bn670.005.702.875.100.4209165.17165.172,257.80327.801.842.2212.7197,135,820.0013.448.4048.1219.2079.8981.347.323.850.844991.330.683928.2613.9453.90923.8057.9251.63--
StemRIM Inc2.35bn179.40m30.00bn44.00142.563.06--12.76-0.1097-0.109737.43159.710.2453----53,409,090.001.87-6.711.89-6.83----7.63-45.8078.90652.720.00--10,128.0663.68108.64------
Mizuho Medy Co Ltd10.99bn3.77bn30.82bn175.008.161.977.762.80396.27396.271,153.851,645.860.57762.042.04--19.8431.4623.7039.7873.4774.8534.3433.646.45----30.50-37.4911.34-51.8532.64-17.7432.85
Data as of Mar 28 2024. Currency figures normalised to Fuso Pharmaceutical Industries Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

10.66%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 29 Feb 2024214.20k2.27%
The Vanguard Group, Inc.as of 07 Mar 2024180.51k1.91%
Dimensional Fund Advisors LPas of 07 Mar 2024180.40k1.91%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Sep 2023157.20k1.66%
Daiwa Asset Management Co. Ltd.as of 29 Feb 202498.30k1.04%
Nikko Asset Management Co., Ltd.as of 15 Sep 202389.80k0.95%
Mitsubishi UFJ Asset Management Co., Ltd.as of 25 Sep 202338.60k0.41%
Norges Bank Investment Managementas of 31 Dec 202326.80k0.28%
Dimensional Fund Advisors Ltd.as of 07 Mar 202411.33k0.12%
Asset Management One Co., Ltd.as of 19 Dec 202310.40k0.11%
More ▼
Data from 30 Nov 2023 - 21 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.